Alpha Healthcare provides Carmell merger update; LOI for commercial stage allograft company with $50M revenue

Longevity Health Holdings, Inc.

Shareholder vote for Carmell merger scheduled July 11, 2023; redemption deadline July 7.
Non-binding LOI to acquire a commercial stage allograft company with ~$50M TTM revenue and ~$5M EBITDA.
Deal terms: $65M initial equity ($8M cash + $57M stock) plus up to $75M milestone payments (12% cash, 88% stock); 12-month lockup.
Carmell's pipeline: Phase 2 tibia fracture trial (Fast Track), FDA agreed HEAL II start; foot/ankle fusion program.
Post-merger ticker CTCX; plan to build leading player in aesthetics and orthopedics through roll-ups.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.